Related Experiment Video
Updated: Jul 7, 2026
09:29
Continuous Video Electroencephalogram during Hypoxia-Ischemia in Neonatal Mice
Published on: June 11, 2020
Pyridoxal phosphate-dependent neonatal epileptic encephalopathy
S Bagci1, J Zschocke, G F Hoffmann
1Centre for Paediatrics, Department of Neonatology, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany.
Archives of Disease in Childhood. Fetal and Neonatal Edition
|February 26, 2008
Summary
Pyridoxal phosphate (PLP) is crucial for neurotransmitter synthesis. A genetic mutation causing neonatal seizures unresponsive to pyridoxine but responsive to PLP highlights PLP
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Pyridox(am)ine-5'-phosphate oxidase (PNPO) is essential for converting vitamin B6 vitamers to pyridoxal phosphate (PLP).
- PLP acts as a cofactor in numerous metabolic pathways, including the synthesis of neurotransmitters.
- Deficiency in PLP can lead to severe neurological dysfunction.
Observation:
- A family presented with neonatal seizures that were refractory to standard treatments like pyridoxine and anticonvulsants.
- Genetic analysis revealed a mutation in the pyridox(am)ine-5'-phosphate oxidase gene in the affected individuals.
- The neonatal seizures showed a remarkable response to pyridoxal phosphate administration.
Findings:
- The identified mutation in the PNPO gene impairs its enzymatic activity, leading to functional PLP deficiency.
- This deficiency directly causes severe neurological symptoms, specifically neonatal epileptic encephalopathy.
- Pyridoxal phosphate supplementation effectively bypasses the enzymatic defect and alleviates seizures.
Implications:
- Pyridoxal phosphate should be considered as a critical therapeutic agent for neonatal epileptic encephalopathy.
- Early diagnosis and treatment with PLP can prevent irreversible neurological damage.
- This finding expands the understanding of vitamin B6 metabolism disorders and their clinical manifestations.
Related Concept Videos
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...